SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report: May 9, 1994
C. R. Bard, Inc.
(Exact name of registrant as
specified in its charter)
New Jersey 1-6926 22-1454160
(State of Commission File Number IRS Employer
Incorporation) Identification No.
730 Central Avenue, Murray Hill, New Jersey 07974
(Address of principal executive offices) (Zip Code)
(908) 277-8000
(Registrant's telephone number)
<PAGE>
Item 5. Other Events
In a news release dated May 6, 1994, C. R. Bard, Inc.
announced that the process of auditing new product submissions of its
USCI division has begun and that the Company is unable to estimate how
long the audit process will take or how long the suspension of FDA
review of USCI's pending premarket applications will last. The news
release, issued by the Company on May 6, 1994, is incorporated herein
by reference, and is attached hereto as Exhibit 1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
C. R. BARD, INC.
(Registrant)
By: William C. Bopp /s/
William C. Bopp
Senior Vice President
and Chief Financial Officer
Dated: May 9, 1994
<PAGE>
Exhibit 1 C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974
News Release
Contact: E. L. Parker
Treasurer
(908) 277-8059
BARD UPDATES STATUS OF PRODUCT SUBMISSION AUDITS
MURRAY HILL, NJ - May 6, 1994 - C. R. Bard, Inc. (NYSE-BCR)
said today that the process of auditing new product submissions
of its USCI division has begun, and that the company is unable
to estimate how long that process will take.
In January, Bard announced that the Food and Drug
Administration's (FDA) Applications Integrity Policy had been
applied to current applications from Bard's USCI division, and
that based upon audits to be conducted by the Company, the FDA
would assess the validity of data and information in USCI's
pending premarket applications. The auditor has been selected
and work began early in April. The Company is unable to
estimate how long the audit process will take or how long the
suspension of FDA review of USCI's pending premarket
applications will last.
William H. Longfield, Bard's president and chief operating
officer, said, "Notwithstanding the continued suspension of
USCI's new product approvals, the first quarter sales strength
experienced by our other businesses is continuing this quarter.
As we stated at our annual meeting in April, Wall Street
analysts' earnings estimates of $1.80 - $1.90 per share for
1994 still appear reasonable to us."
C. R. Bard, Inc., headquartered in Murray Hill, NJ, is a
leading multinational developer, manufacturer and marketer of
health care products.
# # # # # #
